论文部分内容阅读
本文首先测定34株念珠菌、曲菌和隐球菌对两性霉素B、5-氟胞嘧啶、酮康唑、利福平的MIC,然后用棋盘式滴定测定药物的体外联合抗真菌作用。未能证明两性霉素B加5-氟胞嘧啶或酮康唑、5-氟胞嘧啶加酮康唑有协同作用。但两性霉素B和利福平则对34株中的33株有协同抗真菌作用。协同作用对新型隐球菌和白色念珠菌尤为显著。研究了三种药物的体外联合抗真菌作用,加入第三种药物未能显著增加抗真菌活力。在杀菌曲线研究中,两性霉素B和利福平对白色念珠菌B311的协同作用进一步被证实。
In this paper, MIC of Candida, Aspergillus and Cryptococcus to amphotericin B, 5-fluorocytosine, ketoconazole and rifampicin was determined first and then the antifungal effect of the drug in vitro was determined by checkerboard titration. Failed to prove that amphotericin B plus 5-fluorocytosine or ketoconazole, 5-fluorocytosine and ketoconazole synergistic effect. However, amphotericin B and rifampicin had synergistic antifungal effects against 33 out of 34 strains. Synergy of Cryptococcus neoformans and Candida albicans is particularly significant. The in vitro combined antifungal effects of the three drugs were studied, and the addition of the third drug failed to significantly increase antifungal activity. Synergistic effects of amphotericin B and rifampin against Candida albicans B311 were further confirmed in the bacteriocidal curve.